A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the dose of the combination of trabectedin
(Yondelis) and Doxorubicin for which neutropenia (low white blood cell counts) could be
managed with filgrastim (a Granulocyte-Colony Stimulation Factor that is used to help control
neutropenia) in patients with a type of cancer called soft tissue sarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.